PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside
Authors
Keywords
-
Journal
CANCER
Volume 124, Issue 12, Pages 2498-2506
Publisher
Wiley
Online
2018-04-17
DOI
10.1002/cncr.31307
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
- (2018) Sibylle Loibl et al. LANCET ONCOLOGY
- Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer
- (2017) Naama Halpern et al. INTERNATIONAL JOURNAL OF CANCER
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
- (2017) Karoline B. Kuchenbaecker et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
- (2017) Jung-Min Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
- (2017) Johann de Bono et al. Cancer Discovery
- Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors.
- (2017) A. R. Tan et al. JOURNAL OF CLINICAL ONCOLOGY
- A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation
- (2016) J.K. Litton et al. ANNALS OF ONCOLOGY
- Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
- (2016) E. T. Rodler et al. CLINICAL CANCER RESEARCH
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
- (2016) M. L. Telli et al. CLINICAL CANCER RESEARCH
- Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
- (2016) Hope S. Rugo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
- (2016) Kyle C. Strickland et al. Oncotarget
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors
- (2015) T. A. Hopkins et al. MOLECULAR CANCER RESEARCH
- REV7 counteracts DNA double-strand break resection and affects PARP inhibition
- (2015) Guotai Xu et al. NATURE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
- (2015) T. Higuchi et al. Cancer Immunology Research
- Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors
- (2014) J. Balmaña et al. ANNALS OF ONCOLOGY
- Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing
- (2014) Priyanka Sharma et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
- (2014) Joyce O'Shaughnessy et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses
- (2014) Jung-Min Lee et al. JNCI-Journal of the National Cancer Institute
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib
- (2014) Marine Gilabert et al. PLoS One
- Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort
- (2013) Rachel Greenup et al. ANNALS OF SURGICAL ONCOLOGY
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- (2013) Y. Shen et al. CLINICAL CANCER RESEARCH
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
- (2013) Shahneen K Sandhu et al. LANCET ONCOLOGY
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- Classifications within Molecular Subtypes Enables Identification of BRCA1/BRCA2 Mutation Carriers by RNA Tumor Profiling
- (2013) Martin J. Larsen et al. PLoS One
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
- (2012) A. G. Patel et al. CLINICAL CANCER RESEARCH
- Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
- (2012) Janneke E. Jaspers et al. Cancer Discovery
- Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
- (2011) Barbara Norquist et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients
- (2010) M. A. Vollebergh et al. ANNALS OF ONCOLOGY
- Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis
- (2010) Anthony Gonçalves et al. BREAST CANCER RESEARCH AND TREATMENT
- Gene Expression Profile ofBRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
- (2010) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Nuclear phosphoinositide 3-kinase controls double-strand break DNA repair
- (2010) A. Kumar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination
- (2009) Helen E Bryant et al. EMBO JOURNAL
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and Pathologic Characteristics of Patients WithBRCA-Positive andBRCA-Negative Breast Cancer
- (2008) Deann P. Atchley et al. JOURNAL OF CLINICAL ONCOLOGY
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now